Targeted therapy has been proved to have great beneficial in cancers with specific targeting [5], such as the good prognosis in endothelial growth factor receptor- (EGFR-) mutated non-small-cell lung cancer (NSCLC) after treatment with EGFR inhibitors, breast cancer gene- (BRCA-) mutated ovarian cancer with poly-ADP- (adenosine diphosphate-) ribose polymerase (PARP) inhibitors, and treatment of BRAF-mutated cutaneous melanoma, as well as NSCLC with BRAF inhibitors or MEK inhibitors [6–9]. This evidence concerns the gene BRAF and cutaneous melanoma.